HemoShear Gets $4.3M SBIR Grant to Develop Predictive Drug Technologies | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech firm HemoShear today announced a $4.3 million Phase II Small Business Innovation Research grant to profile the effects of 50 known drugs on the human blood vessel system using the company's proprietary human vascular surrogate system.

The grant, the third received by the Charlottesville, Va.-based company in the past two years, is from the National Heart, Lung, and Blood Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.